Periconceptual Progesterone Use and Hypertensive Disorders of Pregnancy: A Population‐Based Cohort Study
Open Access
- 5 November 2026
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Abstract
Objective: To investigate whether periconceptual use of progesterone is associated with an altered risk of new‐onset hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, or superimposed preeclampsia). Design: Population‐based cohort study using statewide pregnancy and birth data from Victoria, Australia, linked with hospital and medication prescribing data. Setting: Victoria, Australia (2009–2020). Population: Nulliparous women who gave birth between 2009 and 2020 in Victoria, Australia. Women with missing delivery dates, medicine dispensation dates, or who were exposed to progesterone in the second or third trimester were excluded. Methods: We compared nulliparous women exposed to progesterone in the periconceptual period (6 weeks preconception until the end of the first trimester) with those not exposed to progesterone. Inverse probability‐weighted regression adjustment was used to control for confounding factors and investigate the effect of progesterone on the risk of preeclampsia (including superimposed preeclampsia) and gestational hypertension. Main Outcome Measures: Development of preeclampsia or gestational hypertension. Results: Among 386 475 pregnancies, 5657 (1.5%) women used progesterone in the periconceptual period. Progesterone use was associated with a statistically significant reduction in the risk of any new onset hypertensive disorders of pregnancy (adjusted risk ratio [aRR] 0.81 [95% confidence interval [CI] 0.67, 0.98]; adjusted risk difference [aRD] −1.72% [95% CI −3.21%, −0.24%]). Investigating type of hypertension, we found progesterone use was associated with a 1.69% absolute reduced risk of gestational hypertension (aRR 0.60 [95% CI 0.43, 0.83]; aRD −1.69% [95% CI −2.52%, −0.86%]) but no significant change was observed for preeclampsia (aRR 0.97 [95% CI 0.75, 1.25]; aRD −0.13% [95% CI −1.49%, 1.23%]). Restricting our analyses to pregnancies conceived via assisted reproductive technology only, we found similar results, with a statistically significant reduction in the risk of gestational hypertension (aRR 0.80 [95% CI 0.67, 0.95]; aRD −1.02% [95% CI −1.73%, −0.30%]) but not preeclampsia (aRR 0.96 [95% CI 0.83, 1.11]; aRD −0.25% [95% CI −1.23%, 0.72%]). Conclusions: Among 386 475 nulliparous women, we found periconceptual progesterone use to be associated with a statistically significant reduction in the risk of gestational hypertension, but not preeclampsia. However, these findings are unlikely to be clinically meaningful.Keywords
Funding Information
- National Health and Medical Research Council (1176922)
- National Health and Medical Research Council (2017897)
- National Health and Medical Research Council (1185467)
- National Health and Medical Research Council (2022019)
- Norman Beischer Medical Research Foundation
- University of Melbourne
This publication has 40 references indexed in Scilit:
- Predictive value of cervical length for spontaneous preterm birth in women with cervical cerclageUltrasound in Obstetrics & Gynecology, 2025
- Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational HypertensionJAMA Network Open, 2025
- The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative reviewVascular Pharmacology, 2023
- Pre-eclampsiaNature Reviews Disease Primers, 2023
- Pre-eclampsiaThe Lancet, 2021
- Antiplatelet agents for preventing pre-eclampsia and its complicationsCochrane Database of Systematic Reviews, 2019
- Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sitesMucosal Immunology, 2017
- Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancyAmerican Journal of Obstetrics and Gynecology, 2014
- Progesterone to prevent spontaneous preterm birthSeminars in Fetal and Neonatal Medicine, 2014
- The Global Impact of Pre-eclampsia and EclampsiaSeminars in Perinatology, 2009